December 5-6, 2023Nobias CEO, Neil Inala, to speak at the AI Driven Drug Discovery Summit USA, Boston, MA
October 10, 2023Nobias Therapeutics Announces Phase 2 Clinical Trial Results for NB-001 at 52nd Child Neurology Society Annual Meeting
September 20, 2023Nobias Therapeutics Announces Acceptance of Late-Breaking Abstract and Presentation of Phase 2 Clinical Data for NB-001 at 52nd Child Neurology Society Annual Meeting
